The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.

BioNTech has appointed Guido Oelkers, former CEO of Swedish rare-disease company Sobi, as its next chief executive, effective February 1, 2027. Oelkers will succeed co-founder Uğur Şahin as BioNTech transitions from a COVID vaccine-focused company to one with a diversified oncology pipeline. The appointment represents a planned transition rather than a strategic shift, with Oelkers' commercial and acquisition experience expected to guide the company through multiple product launches later this decade.

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

BioNTech will announce its second quarter 2026 financial results on August 4, 2026, followed by a conference call. The company will showcase progress across its late-stage oncology pipeline at ASCO 2026, including encouraging efficacy data from the ROSETTA Lung-02 trial for its PD-L1xVEGF-A bispecific pumitamig in non-small cell lung cancer patients, developed in partnership with Bristol Myers Squibb.

BioNTech will release second quarter 2026 financial results on August 4, 2026, followed by a conference call. The company will showcase progress across its late-stage oncology pipeline at ASCO 2026, including data on its PD-L1xVEGF-A bispecific pumitamig developed with Bristol Myers Squibb, which demonstrated encouraging efficacy in non-small cell lung cancer patients.

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

Pfizer and Bristol Myers Squibb are presented as attractively valued dividend stocks despite recent challenges. Both pharmaceutical companies face patent cliffs but have strong pipelines with promising candidates in oncology, weight loss, and anticoagulants. With forward yields of 7.1% and 4.3% respectively, and trading at discounted valuations (8.2x and 9x forward earnings), they are recommended as potential buys for dividend investors with $1,000 to deploy.

BioNTech and Bristol Myers Squibb announced interim results from the ROSETTA Lung-02 Phase 2/3 study showing that their bispecific PD-L1xVEGF-A immunomodulator candidate Pumitamig demonstrated encouraging anti-tumor activity in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). The drug showed confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous NSCLC subtypes at the lower dose, with consistent efficacy across all PD-L1 expression levels. The companies are advancing a comprehensive global Phase 3 development program with multiple ongoing trials.

BioNTech and Bristol Myers Squibb announced interim Phase 2 data from the ROSETTA Lung-02 trial showing that their investigational bispecific immunomodulator pumitamig combined with chemotherapy demonstrated encouraging anti-tumor activity in first-line non-small cell lung cancer, with confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous subtypes at the lower dose. The drug showed consistent efficacy across PD-L1 expression levels with a manageable safety profile, and is advancing through a comprehensive Phase 3 development program.

BioNTech will present clinical data at ASCO 2026 showing encouraging anti-tumor activity for pumitamig in combination with chemotherapy across multiple cancer types, and positive overall survival data for gotistobart in platinum-resistant ovarian cancer. The company is advancing 25+ Phase 2/3 trials including 13 pivotal trials across its diversified oncology pipeline.

BioNTech will present clinical data at the 2026 ASCO Annual Meeting on late-stage oncology pipeline programs, including positive Phase 2 data from ROSETTA Lung-02 for Pumitamig (in combination with chemotherapy for non-small cell lung cancer) and overall survival data for Gotistobart in platinum-resistant ovarian cancer. The company is advancing a diversified portfolio with over 25 Phase 2/3 clinical trials, including 13 ongoing registration-relevant studies.